|By PR Newswire||
|April 14, 2014 06:06 AM EDT||
SUN CITY, Ariz., April 14, 2014 /PRNewswire/ -- Banner Sun Health Research Institute is proud to announce it is one of just five facilities in the United States to launch a new clinical trial for patients with mild to moderate Alzheimer's disease (AD). This study, titled "Effect of NeuroAD™, Combined TMS Stimulation and Cognitive Training, on the cognitive function of mild to moderate Alzheimer patients," utilizes NeuroAD technology, a noninvasive approach to reduce memory decline as a result of AD.
The NeuroAD system by Neuronix is an innovative, non-pharmaceutical treatment alternative for the treatment of mild to moderate Alzheimer's disease. This cutting-edge study involves non-invasive, Transcranial Magnetic Stimulation (TMS) and cognitive exercises in the NeuroAD chair. The device sends magnetic waves into the brain. This stimulation combined with cognitive exercises is expected to result in a measurable cognitive improvement after just a few weeks of treatment.
"Preliminary studies demonstrate that this is a safe and potentially effective treatment for Alzheimer's disease," said Marwan Sabbagh, MD, the director at Banner Sun Health Research Institute and Principal Investigator for the study at the facility. "There hasn't been a new treatment for Alzheimer's in a long time, which makes this particularly exciting."
The study being conducted at Banner Sun Health Research Institute, located at 10515 W. Santa Fe Dr. in Sun City, is looking for patients with mild to moderate AD to participate. After screening to determine eligibility, participants would come in for the NeuroAD treatment one hour a day, five days a week for six weeks.
Alzheimer's disease is a degenerative and terminal disease affecting cognitive ability. Early symptoms of AD include difficulty in remembering names and recent events, apathy and depression.
Patients interested in participating in this trial, or for more information, are asked to contact the Banner Sun Health Research Institute at (623) 832-6526.
About Banner Sun Health Research Institute
For 26 years, Banner Sun Health Research Institute, part of nonprofit Banner Health, has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer's and Parkinson's disease. The institute, together with its Arizona Alzheimer's Consortium partners, has been designated by the National Institutes of Health as one of just 29 Alzheimer's disease Centers in the nation. The institute's Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. Banner Health is Arizona's leading health care provider and second largest private employer. For more information, visit www.bannershri.org
About Neuronix Medical
Founded in 2008, Neuronix Medical's mission is to find a method for modifying the course of treatment of Alzheimer's disease (AD), and thus provide long-term improvement in the quality of life for patients. Led by a highly motivated management team and supported by key opinion leaders in the field, Neuronix holds all the basic elements for becoming a leading medical device company, and fulfilling its vision to provide relief for millions of AD patients worldwide. The company's solution, NeuroAD™, is based on a novel, patent pending technology, using stimulation of affected brain regions concurrently interlaced with cognitive training, directed at specific brain regions affected by the disease. The stimulation induces LTP (Long Term Potentiation), which is associated with learning and memory processes, and results in a measurable cognitive improvement after just a few weeks of treatment. For more information, visit www.neuronixmedical.com.
Contact: Jen Fenter, Public Relations
SOURCE Banner Sun Health Research Institute
Oct. 21, 2016 08:15 PM EDT Reads: 288
Oct. 21, 2016 07:15 PM EDT Reads: 1,605
Oct. 21, 2016 07:15 PM EDT Reads: 216
Oct. 21, 2016 07:00 PM EDT Reads: 8,083
Oct. 21, 2016 07:00 PM EDT Reads: 8,921
Oct. 21, 2016 06:45 PM EDT Reads: 2,812
Oct. 21, 2016 06:45 PM EDT Reads: 1,854
Oct. 21, 2016 06:15 PM EDT Reads: 3,004
Oct. 21, 2016 05:15 PM EDT Reads: 597
Oct. 21, 2016 05:15 PM EDT Reads: 2,813
Oct. 21, 2016 04:30 PM EDT Reads: 3,790
Oct. 21, 2016 04:15 PM EDT Reads: 1,481
Oct. 21, 2016 04:15 PM EDT Reads: 916
Oct. 21, 2016 04:00 PM EDT Reads: 1,467
Oct. 21, 2016 04:00 PM EDT Reads: 2,687